Lumida
/CLDX
⌘K
Celldex Therapeutics Inc

Celldex Therapeutics Inc

CLDX
$35.35USD↓-0.14%-0.05 today

MARKET CAP

2.8B

P/E (TTM)

—

FWD P/E

—

DAY RANGE

$34 – $36

52W RANGE

$20
$40

AI Summary

Stalk
StalkMedium

CLDX remains in Stage 2 advancing within an intact long-term uptrend but is undergoing a sharp corrective pullback after a terminal blow-off top. Medium-term bias stays bullish as price holds above the rising 50-DMA and overall HH/HL structure. Short-term timing is unfavorable, with price below the 9- and 21-EMAs and momentum down, so we will stalk a pullback into the 50-DMA support zone for absorption before re-engaging.

  • ↑Phase 2: 71% complete response at week 76 in CSU.
  • ↑Cash position: $408M funds clinical trials through 2025.
  • ↓Negative profitability factors indicate poor return generation.
Full analysis →

The case for & against

Bull & Bear analysis

Bearish

Celldex Therapeutics, Inc. (NASDAQ: CLDX) is an emerging biotechnology company specializing in the development of innovative immunotherapeutic products aimed at treating cancers and mast cell-mediated disorders. The company is strategically focused on its lead candidate, Barzavolumab, which is advancing through clinical trials for chronic spontaneous urticaria (CSU). Celldex is positioned within the healthcare sector, primarily targeting significant unmet medical needs through its unique therapeutic approaches, particularly in an environment increasingly attentive to patient quality of life and innovative treatment modalities.

Bull says

  • ↑Phase 2: 71% complete response at week 76 in CSU.
  • ↑Cash position: $408M funds clinical trials through 2025.
  • ↑Unique mast-cell mechanism differentiates Barzavolumab from omalizumab.
  • ↑92% of CSU patients report daily-life impairment, highlighting demand.
  • ↑Long-term data suggest potential disease-modifying benefits.
  • ↑Positive momentum and high hedge fund ownership signal interest.

Bear says

  • ↓Negative profitability factors indicate poor return generation.
  • ↓Weak earnings yield factors highlight low investor returns.
  • ↓Elevated leverage risk implies financial fragility under stress.
  • ↓Phase III failure or delay could derail approval prospects.
  • ↓Competition from omalizumab and Dupixent may limit market share.
  • ↓Safety issues on neutrophils and spermatogenesis may deter adoption.

Investment themes with CLDX

Biotech↓ -3.20%

Genetic and drug innovations driving medical breakthroughs

APLS · RVMD · SMMT

Earnings Call · Q4 2021 · Mgmt. Guidance

Updated 06-21-2026bullish

Transcript signals

Bull points

  • This is Timor again. Joe, I think we're, as you know, in the expansion cohorts for both of those programs, and our view is we'd like to complete enrollment into those expansion cohorts, and then we'd have something more meaningful to say about the next steps for each of those.
  • our Phase II CSU and CINDU trials are on track and expected to initiate later in the second quarter of this year, an important next step for this program.
  • We are confident we have identified the appropriate therapeutic doses to advance into our Phase II clinical studies.

Bear points

  • Yeah, it's been started and we'll complete it sometime this year. But it has been started. Work is already being done.
  • we did not observe any effects in terms of from a histology analysis of female reproductive organs. So that certainly is very, very comforting.
Read full transcript analysis ›